Skip to main content
SpringerLink
Log in
Book cover

PEGylated Protein Drugs: Basic Science and Clinical Applications pp 1–9Cite as

Preface PEGylated protein conjugates: A new class of therapeutics for the 21st century

  • Chapter

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

The collected Chapters in this volume describe the current status of poly(ethylene glycol) (PEG) modification of proteins, peptides, oligonucleotides and small molecule drugs, the recent advances in conjugation chemistry, and new clinical products. The book provides an excellent update in this rapidly evolving field, and the comprehensive collection of Chapters complements well past reviews/volumes that have documented the evolution of PEGylation. For example, a reader new to this field is encouraged to gain the historical perspective by reading the following reviews [1–8]. Only then is it possible to see just how far this field has come and understand that it has already established a new class of therapeutics as we start the 21st Century!

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Fuertges F, Abuchowski A (1990) The clinical efficacy of poly(ethyleneglycol)-modified proteins. J Controlled Rel 11: 139–148

    Article  CAS  Google Scholar 

  2. Nucci ML, Shorr R, Abuchowski A (1991) The therapeutic values of poly(ethylene glycol)-mod-ified proteins. Adv Drug Delivery Rev 6: 133–151

    Article  CAS  Google Scholar 

  3. Francis GE, Delgado C, Fisher D, Malik F, Argrawl AK (1996) Polyethylene glycol modification: Relevance to improved methodology to tumour targeting. J Drug Targeting 3: 321–340

    Article  CAS  Google Scholar 

  4. Davis FF (2002) The origin of pegnology. Adv Drug Del Rev 54: 457–458

    Article  CAS  Google Scholar 

  5. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nature Rev Drug Discov 2: 214–221

    Article  CAS  Google Scholar 

  6. Veronese FM, Harris JM (Eds) (2002) Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev 54: 453–609

    Google Scholar 

  7. Harris JM, Veronese FM (Eds) Pegylation of peptides and proteins II — Clinical Evaluation. Adv Drug Deliv Rev 55: 1261–1277

    Google Scholar 

  8. Veronese FM, Harris JM (Eds) (2008) Pegylation of peptides and proteins III: Advances in chemistry and clinical applications. Adv Drug Deliv Rev 60: 1–87

    Google Scholar 

  9. Duncan R (2005) Targeting and intracellular delivery of drugs. In: RA Meyers (ed.): Encyclopedia of Molecular Cell Biology and Molecular Medicine. Wiley-VCH Verlag, GmbH & Co. KGaA, Weinheim, Germany, 163–204

    Google Scholar 

  10. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nature Rev Drug Discov 2: 750–763

    Article  CAS  Google Scholar 

  11. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nature Rev Drug Discov 4: 145–160

    Article  CAS  Google Scholar 

  12. Couvreur P, Vauthier C (2006) Nanotechnology: Intelligent design to treat complex disease. Pharm Res 23:1417–1450

    Article  CAS  PubMed  Google Scholar 

  13. Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2: 347–360

    Article  CAS  PubMed  Google Scholar 

  14. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6: 688–701

    Article  CAS  PubMed  Google Scholar 

  15. US Food and Drug Administration accessed at http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/

    Google Scholar 

  16. Ferrari M (2005) Cancer nanotechnology: Opportunities and challenges. Nature Rev Cancer 5: 161–171

    Article  CAS  Google Scholar 

  17. European Science Foundation Forward Look on Nanomedicine (2005) http://www.esf.org

    Google Scholar 

  18. Ringsdorf H (2004) Hermann Staudingerand the Future of Polymer Research: Jubilees — Beloved Occasions for Cultural Piety. Angew Chem Int Ed 43: 1064–1076

    Article  CAS  Google Scholar 

  19. Gros L, Ringsdorf H, Schupp H (1981) Polymerie antitumour agents on a molecular and cellular level. Angew Chemie Int Ed Eng 20: 301–323

    Article  Google Scholar 

  20. Regelson W, Parker G (1986) The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. Cancer Invest 4: 29–42

    Article  CAS  PubMed  Google Scholar 

  21. Ringsdorf H (1975) Structure and properties of pharmacologically active polymers. J Polymer Sci Polymer Symp 51:135–153

    Article  CAS  Google Scholar 

  22. Lee CC, MacKay JA, Fréchet JMJ, Szoka FC (2005) Designing dendrimers for biological applications. Nature Biotechnol 23: 1517–1526

    Article  CAS  Google Scholar 

  23. Ng EWM, Shima DT, Calias P, Cunningham Jr ET, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Rev Drug Discov 5:125–132

    Article  CAS  Google Scholar 

  24. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, Deventer SV, Goldblum R, Despain D, Hogge GS, Rutgeerts P (2005) Natalizumab induction and maintenance therapy for Crohn’s disease N Engl J Med 353(18): 1912–1935

    Article  CAS  PubMed  Google Scholar 

  25. Eldar-Lissai A, Cosier LE, Culakova E, Lyman GH (2008) Economic analysis of prophylactic peg-filgrastim in adult cancer patients receiving chemotherapy. Value Health 11: 172–179

    Article  PubMed  Google Scholar 

  26. Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y (2007) A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg 70: 177–187

    PubMed  Google Scholar 

  27. Eaton M (2007) Nanomedicine: industry-wise research, Nature Mater 6: 251–253

    Article  CAS  Google Scholar 

  28. Gaspar R (2007) Regulatory issues surrounding nanomedicines: setting the scene for the nextgeneration of nanopharmaceuticals. Nanomedicine 2: 143–147

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Polymer Therapeutics, Welsh School of Pharmacy, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, UK

    Ruth Duncan

  2. Department of Pharmaceutical Sciences, University of Padua, Via F. Marzolo 5, 35131, Padua, Italy

    Francesco M. Veronese

Authors
  1. Ruth Duncan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco M. Veronese
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmaceutical Sciences, University of Padova, 35131, Padova, Italy

    Francesco M. Veronese

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Duncan, R., Veronese, F.M. (2009). Preface PEGylated protein conjugates: A new class of therapeutics for the 21st century. In: Veronese, F.M. (eds) PEGylated Protein Drugs: Basic Science and Clinical Applications. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8679-5_1

Download citation

Publish with us

Policies and ethics

Search

Navigation